[Probiotics' position in clinical practice: focus on the combination of <i>Lactobacillus acidophilus</i> (LA-5) and <i>Bifidobacterium animalis</i> subsp. <i>lactis</i> (BB-12). A review].
- 2026-02-14
- Terapevticheskii arkhiv 97(12)
- A V Gorelov
- R S Kozlov
- I V Andreeva
- A A Arova
- I A Bavykina
- M S Grigorovich
- E V Dovgan
- K D Ermolenko
- O V Zaytseva
- S M Zakharenko
- V V Zelenskaia
- S K Zyryanov
- N A Ilyenkova
- M A Kachkovskii
- T A Kogut
- E G Kondyurina
- V V Krasnov
- E E Lokshina
- V F Privorotsky
- M N Repetskaya
- M F Rzyankina
- S N Serikova
- O U Stetsiouk
- D V Usenko
- L V Khanipova
- A M Shabalov
- M A Shevyakov
- L V Yakovleva
- PubMed: 41705617
- DOI: 10.26442/00403660.2025.12.203481
Probiotics are currently widely used in clinical practice to prevent and treat a wide range of diseases. The purpose of our review is to highlight what we consider to be the most significant clinical studies on the use of probiotics for preventing antibiotic-associated diarrhea, clostridial diarrhea and pseudomembranous colitis. The article also presents the results of studies confirming the efficacy of probiotics in Helicobacter pylori eradication therapy. The review focuses on Linex® Forte, medicinal product containing the combination of Lactobacillus acidophilus (LA-5) and Bifidobacterium animalis subsp.lactis (BB-12).
Research Insights
| Supplement | Health Outcome | Effect Type | Effect Size |
|---|---|---|---|
| Bifidobacterium animalis subsp. lactis BB-12 | Increased Helicobacter pylori Eradication Rate | Beneficial | Small |
| Bifidobacterium animalis subsp. lactis BB-12 | Reduced Antibiotic-Associated Diarrhea | Beneficial | Moderate |